Boehringer Ingelheim: ESOC 2019 – How NOAC selection and reversal can help protect our patients: Your questions answered

1) Keeping pace with advances in anticoagulation – Stephen Davis, Australia

 

2) What is the evidence for dabigatran? – Richard A. Bernstein, USA

 

3) What is the evidence for NOAC reversal strategies? – Sheila Martins, Brazil

 

4 How do we manage dabigatran and idarucizumab in neurological emergencies – Martin Grond, Germany